TABLE 2.
Outcome probabilities (with 95% confidence interval) stratified by conditioning intensity and TRM score
| CI of NRM at 100 days | CI of NRM at 3 years | CI of relapse at 3 years | RFS at 3 years | OS at 3 years | |
|---|---|---|---|---|---|
| All patients (n=861) | 5% (4–7%) | 17% (15–20%) | 31% (28–34%) | 51% (48–55%) | 57% (54–61%) |
| TRM score | |||||
| 1st quartile (n=215) | 4% (2–7%) | 9% (5–13%) | 26% (20–32%) | 66% (59–72%) | 72% (66–78%) |
| 2nd quartile (n=215) | 4% (2–7%) | 15% (10–20%) | 25% (19–31%) | 60% (53–66%) | 65% (58–71%) |
| 3rd quartile (n=216) | 3% (1–6%) | 18% (13–24%) | 37% (30–43%) | 45% (38–51%) | 53% (46–60%) |
| 4th quartile (n=215) | 9% (6–13%) | 28% (22–34%) | 37% (30–43%) | 36% (29–42%) | 39% (33–46%) |
| MAC HCT (n=544) | 5% (3–7%) | 13% (10–16%) | 28% (24–32%) | 59% (55–63%) | 64% (59–68%) |
| TRM score | |||||
| 1st quartile (n=183) | 3% (2–7%) | 8% (4–12%) | 26% (20–33%) | 66% (58–72%) | 71% (64–77%) |
| 2nd quartile (n=158) | 5% (2–9%) | 14% (9–20%) | 22% (16–29%) | 65% (56–72%) | 68% (60–75%) |
| 3rd quartile (n=123) | 2% (0–5%) | 13% (8–20%) | 32% (24–40%) | 55% (45–63%) | 61% (52–69%) |
| 4th quartile (n=80) | 11% (6–19%) | 25% (16–35%) | 37% (26–47%) | 39% (28–50%) | 43% (32–54%) |
| Non-MAC HCT (n=317) | 5% (3–8%) | 25% (20–30%) | 37% (31–42%) | 39% (33–44%) | 47% (41–52%) |
| TRM score | |||||
| 1st quartile (n=32) | 6% (1–18%) | 13% (4–27%) | 23% (10–39%) | 64% (45–79%) | 81% (62–91%) |
| 2nd quartile (n=57) | 2% (0–8%) | 19% (10–31%) | 34% (22–47%) | 47% (33–60%) | 56% (42–69%) |
| 3rd quartile (n=93) | 4% (1–10%) | 25% (17–35%) | 43% (33–53%) | 31% (22–41%) | 43% (32–53%) |
| 4th quartile (n=135) | 7% (4–13%) | 29% (22–37%) | 36% (28–45%) | 34% (26–42%) | 37% (29–45%) |
Abbreviations: CI, cumulative incidence; HCT, hematopoietic cell transplantation; MAC, myeloablative conditioning; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival.